June 4, 2026

A new exploratory analysis from STAMP (EA6174) on aggressive Merkel cell cancer draws attention at ASCO 2026

June 2, 2026

EA5142, an ALCHEMIST trial, adds to the knowledge base about optimal timing of adjuvant immunotherapy in non-small cell lung cancer

June 2, 2026

WATCH: Dr. Jamie Chaft discusses the results of ALCHEMIST EA5142, a randomized phase 3 study of nivolumab after surgery and adjuvant chemotherapy in non-small cell lung cancer

June 1, 2026

JAMA publishes ALCHEMIST EA5142 results: Nivolumab does not further reduce the risk of recurrence in patients with resected non-small cell lung cancer

April 8, 2026

ECOG-ACRIN vice chair Dr. Al Benson discusses the evolving role of first-line immunotherapy for advanced anal cancer, referencing the InterAACT-2 and EA2176 trials

April 8, 2026

Group co-chair Dr. Mitchell Schnall named a health system chief digital officer to know in 2026

March 30, 2026

The March 2026 News from ECOG-ACRIN blog is now available

March 24, 2026

ECOG-ACRIN study finds inferior survival among Black patients with AML, independent of cytogenetic risk

February 27, 2026

Attention medical and research trainees: Applications are now being accepted for the Edith Peterson Mitchell, MD, Health Equity Travel Scholarship to attend the Spring 2026 Group Meeting

ECOG-ACRIN Cancer Research Group